Citigroup Reinstates Buy on Ligand Pharmaceuticals, Announces $387 Price Target
Citigroup analyst Yigal Nochomovitz reinstates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and announces $387 price target.
A big bank's analyst thinks Ligand Pharmaceuticals is a good company to own and predicts it could be worth $387 per share. When experts become more confident about a company, it can hint that they see something improving in the business.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.